• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Vincent A. Miller, Vera Hirsh, +15 authors James Chih‐Hsin Yang
  • Medicine
  • The Lancet. Oncology
  • 2012 (First Publication: 1 May 2012)
  • BACKGROUND Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. WeExpand
  • Li Zhang, Shenglin Ma, +13 authors Mengzhao Wang
  • Medicine
  • The Lancet. Oncology
  • 2012 (First Publication: 1 May 2012)
  • BACKGROUND Maintenance treatment of patients with advanced non-small-cell lung cancer (NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing research. The aim ofExpand
  • Yuankai Shi, Junling Li, +16 authors Xiaohong Han
  • Medicine
  • PloS one
  • 2015 (First Publication: 23 November 2015)
  • Epidermal growth factor receptor (EGFR) mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) therapy, but knowledge of the EGFR mutation frequency on lungExpand
  • Ran Ran, Longyun Li, Mengzhao Wang, Shulan Wang, Zhi Zheng, Peter Ping Lin
  • Chemistry, Medicine
  • Analytical and Bioanalytical Chemistry
  • 2013 (First Publication: 5 July 2013)
  • AbstractA minimally invasive and repeatable approach for real-time epidermal growth factor receptor (EGFR) mutation surveillance would be highly beneficial for individualized therapy of late stageExpand
  • Hongyun Zhao, Yun Fan, +13 authors Li Zhang
  • Medicine
  • Journal of thoracic oncology : official…
  • 2015 (First Publication: 1 April 2015)
  • Background: The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with advanced non–small-cellExpand